During Wednesday’s Current trade, Shares of Starwood Hotels & Resorts Worldwide Inc (NYSE:HOT), lost -0.10% to $69.90.
Starwood Hotels & Resorts Worldwide, Inc. (HOT) declared its long-established presence in Brazil will expand with the signing of Sheraton® Santos Hotel, owned by local real estate developer Grupo Mendes, marking the company’s 10th hotel in the country. The signing comes on the heels of the recent reopening of Sheraton Barra Rio de Janeiro Hotel in May and, fitting for the Sheraton brand, will be the first international upper-upscale hotel in Santos in the state of São Paulo.
The new-build Sheraton Santos Hotel is part of a mixed used development that comprises residences, offices and retail space. Located in an upscale residential area and within walking distance to the beach, the hotel is adjacent to Shopping Praiamar, the city’s high-end mall, and will comprise 213 guestrooms featuring the Sheraton brand’s contemporary design. The property will offer all of the Sheraton brand’s signature amenities, counting an ultramodern Sheraton Club Lounge, a lobby bar serving the brand’s latest food and beverage program Paired, a signature restaurant, the Shine Spa for Sheraton™, a pool and state-of-the-art fitness facilities.
Starwood Hotels & Resorts Worldwide, Inc., together with its auxiliaries, operates as a hotel and leisure company worldwide. The company owns, operates, and franchises luxury and upscale full-service hotels, resorts, residences, retreats, select-service hotels, and extended stay hotels under the St. Regis, The Luxury Collection, W, Westin, Le Méridien, Sheraton, Four Points, Aloft, and Element brand names.
Shares of Arthur J. Gallagher & Co. (NYSE:AJG), declined -0.43% to $42.10, during its current trading session.
Arthur J. Gallagher & Co. (AJG) declared the acquisition of North Alabama Insurance, Inc. in Florence, Alabama. Terms of the transaction were not revealed.
Established in 1982, North Alabama Insurance, Inc. (NAI) is a managing general agent and wholesale insurance broker which provide property/casualty, commercial auto/garage and other specialty insurance placements to their independent retail insurance broker clients throughout the south central United States. Joshua Blevins, John Speir and their associates will continue to operate from their current locations in Florence and Cabot, Arkansas under the direction of Joel Cavaness, President of Risk Placement Services, Inc., a partner of Arthur J. Gallagher & Co.
Arthur J. Gallagher & Co., together with its auxiliaries, provides insurance brokerage and risk administration services in the United States and internationally. It operates through three segments: Brokerage, Risk Administration, and Corporate.
Incyte Corporation (NASDAQ:INCY), during its Wednesday’s current trading session gained 0.63% to $118.52.
Incyte Corporation (Nasdaq: INCY) declared it will present at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference on Thursday, October 1, 2015 at 3:15 p.m. (EDT) in New York.
The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. Investors interested in listening to the live webcast should log on before the start time in order to download any software required. A replay of the presentation will be accessible.
ncyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), counting primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF.
Finally, Intrexon Corp (NYSE:XON), gained 2.87%, to $47.30.
Synthetic Biologics, Inc in partnership with Intrexon Corporation (XON), a monoclonal antibody combination for the treatment of Pertussis and biotherapeutics for the treatment of phenylketonuria (PKU). Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, presented data from its novel SYN-004 program that demonstrated SYN-004 protected the gut microbiome from damage often caused by the intravenous (IV) beta-lactam antibiotic, ceftriaxone, in a pilot study of humanized pigs. The data were presented yesterday in a late-breaker oral presentation at the 2015 Interscience Conference of Antimicrobial Agents and Chemotherapy and International Congress of Chemotherapy and Infection joint meeting (ICAAC/ICC 2015) in San Diego, CA.
SYN-004 is the Company’s candidate therapy, presently in Phase 2 clinical trials, that is designed to degrade certain IV beta-lactam antibiotics within the gastrointestinal (GI) tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, antibiotic-associated diarrhea (AAD) and secondary antibiotic-resistant infections. C. difficile is frequently associated with IV antibiotic treatment and is the leading type of hospital attained infection accounting for more than 1.1 million infectionsi and 30,000 related deathsii each year in the United States.
Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that comprise of key genetic components.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
